{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T01:16:50Z","timestamp":1789521410756,"version":"build-2803163510"},"reference-count":12,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"unspecified","delay-in-days":89,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,3,6]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Published evidence is limited on the clinical burden of juvenile myasthenia gravis (JMG). We aimed to assess epidemiology and the clinical characteristics of JMG in England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a retrospective analysis of patients with newly diagnosed JMG identified in England via primary care and hospital data between 2010 and 2019.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>32 children (aged 2\u201317 years) with newly diagnosed JMG were included. Prevalence of JMG ranged from 2.2 (95% CI 1.5 to 3.1) in 2012 to 2.5 (95% CI 1.8 to 3.4) per 100\u2009000 in 2018. The annual incidence ranged from 0.8 (95% CI 0.1 to 5.7) in 2015 to 3.8 (95% CI 1.6 to 9.0) per million per year in 2017. Incidence fluctuated in females from 1.6 (95% CI 0.2 to 11.3) in 2016 to 6 (95% CI 2.3 to 16.1) per million per year in 2018. Overall, 20 patients received first acetylcholinesterase inhibitors or corticosteroids with no prior therapy during the study period. During the follow-up period (median, 3.3 years), 17 patients (53.1%) with JMG experienced a hospitalisation. No deaths were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirms the rarity of JMG in England, with steady incidence and prevalence rates over a decade. Further research is required to assess unmet needs in JMG therapy and the importance of effective treatments for this condition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjno-2024-001000","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T02:30:59Z","timestamp":1743474659000},"page":"e001000","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology and 10-year clinical care of juvenile myasthenia gravis in England: a retrospective cohort study"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-4765","authenticated-orcid":false,"given":"ALI","family":"Abbasi","sequence":"first","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerina","family":"Bonar","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zaremba","sequence":"additional","affiliation":[{"name":"UCB, Warszawa, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Scowcroft","sequence":"additional","affiliation":[{"name":"UCB Pharma, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid","family":"Nilius","sequence":"additional","affiliation":[{"name":"UCB, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tennigkeit","sequence":"additional","affiliation":[{"name":"UCB, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham and University of Birmingham, Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sithara","family":"Ramdas","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, MDUK Oxford Neuromuscular Centre, University of Oxford, Oxford, UK"},{"name":"Department of Paediatric Neurology, John Radcliffe Hospital, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"key":"2025072811461904000_7.1.e001000.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00297-0"},{"key":"2025072811461904000_7.1.e001000.2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-333097"},{"key":"2025072811461904000_7.1.e001000.3","doi-asserted-by":"publisher","DOI":"10.3233\/JND-140045"},{"key":"2025072811461904000_7.1.e001000.4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejpn.2016.09.001","article-title":"Juvenile myasthenia gravis in Norway: A nationwide epidemiological study","volume":"21","author":"Popperud","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"2025072811461904000_7.1.e001000.5","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304788"},{"key":"2025072811461904000_7.1.e001000.6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000311012","article-title":"Nationwide Population-Based Epidemiological Study of Myasthenia Gravis in Taiwan","volume":"35","author":"Lai","year":"2010","journal-title":"Neuroepidemiology"},{"key":"2025072811461904000_7.1.e001000.7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nmd.2020.02.001","article-title":"242nd ENMC International Workshop: Diagnosis and management of juvenile myasthenia gravis Hoofddorp, the Netherlands, 1\u20133 March 2019","volume":"30","author":"Munot","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"2025072811461904000_7.1.e001000.8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology (ECronicon)"},{"key":"2025072811461904000_7.1.e001000.9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0805-y"},{"key":"2025072811461904000_7.1.e001000.10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/mus.27791","article-title":"Treatment patterns in myasthenia gravis: A United States health claims analysis","volume":"67","author":"Mahic","year":"2023","journal-title":"Muscle and Nerve"},{"key":"2025072811461904000_7.1.e001000.11","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025072811461904000_7.1.e001000.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-022-02692-4","article-title":"A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis","volume":"22","author":"Harris","year":"2022","journal-title":"BMC Neurol"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2024-001000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T18:46:28Z","timestamp":1753728388000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2024-001000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,3,31]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjno-2024-001000"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2024-001000","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}